Status
Conditions
Treatments
About
Patients will be randomized to Gradual or immediate Goal-dose EN group at day 3 after abdominal surgery. Patients will receive Goal-dose EN gradually or immediately after abdominal surgery. Both groups will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital. The primary and secondary outcomes will be collected.
Full description
Patients after abdominal surgery will receive enteral nutrition for 2 days, if she/he can tolerate 30% of goal-dose EN, then she/he will be randomized to Gradual or immediate Goal-dose EN group at day 3. Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both groups will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first. The primary and secondary outcomes will be collected.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Psychiatric disorders
Pregnancy or breast-feeding women
Malnutrition
Unstable vital signs or unstable hemodynamics (such as systolic blood pressure < 90 mmHg or mean arterial pressure < 70 mmHg after rapid 500 ml crystal or 200 ml gel infusion, or the 50% increase of vascular active drug infusion rate in an hour, etc)
Refuse to participate in the study
Mortality rates expected to more than 50% in 6 months with malignant or irreversibility diseases
Life expectancy less than 24 hours of dying patients
Refractory shock to meet any of the following article
Hepatic insufficiency (alanine/aspartate transaminase/bilirubin 200% above normal range)
Renal insufficiency(creatinine 200% above normal range)
Metabolic diseases(hyperthyroidism/ hypothyroidism, adrenal cortex disorders)
EN can not reach 30% of target energy in 48 hours after surgery
Burn area exceeding 20% of the patient's body surface
Autoimmune diseases or immune dysfunction or history of organ transplantation
International standardization ratio (INR) more than 3.0 or platelet count < 30000 cells/mm3 or other hemorrhagic diathesis
Intracranial hemorrhage one month before enrolment
General contraindications to infusion therapy or history of severe allergy against ingredients of enteral and parenteral nutrition
Has already participated in another clinical trial
Has started to nutritional support therapy before enrolment
Diabetes mellitus (anamnestic and/or under medical treatment)
Primary purpose
Allocation
Interventional model
Masking
411 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal